Current Report Filing (8-k)
May 27 2020 - 07:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 27,
2020
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware |
|
001-37526 |
|
26-0389433 |
(State or Other
Jurisdiction of
Incorporation or
Organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8–K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
¨ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
¨ |
Soliciting material
pursuant to Rule 14a–12 under the Exchange Act (17 CFR
240.14a–12) |
¨ |
Pre–commencement
communications pursuant to Rule 14d–2(b) under the
Exchange Act (17 CFR 240.14d–2(b)) |
¨ |
Pre–commencement
communications pursuant to Rule 13e–4(c) under the
Exchange Act (17 CFR 240.13e–4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
Title of
each class |
|
Trading
Symbol(s) |
|
Name of
each exchange on which registered |
Common Stock, $0.001 par
value per share |
|
ZYNE |
|
The NASDAQ Global
Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. x
On May 27, 2020, Zynerba Pharmaceuticals, Inc. (the “Company”)
issued a press release announcing positive top line data from the
Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of
ZYN002 Administered as a Transdermal Gel to Children and
Adolescents with Autism Spectrum Disorder) clinical trial. A copy
of this press release is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
Attached as Exhibit 99.2 is a presentation that the Company will
post on its website on May 27, 2020 and may use from time to time
in presentations or discussions with investors, analysts or other
parties.
|
Item 9.01 |
Financial Statements and
Exhibits |
The following exhibits are being filed herewith:
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Date: May 27, 2020
|
ZYNERBA
PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Suzanne
Hanlon |
|
|
Name:
Suzanne Hanlon |
|
|
Title:
Secretary, Vice President and General Counsel |